| Assessment Status | Rapid review complete |
| HTA ID | - |
| Drug | Emtricitabine/tenofovir alafenamide |
| Brand | Descovy® |
| Indication | In combination with other antiretroviral agents (ARVs) for the treatment of adults and adolescents (≥12 years; body weight ≥35 kg) infected with human immunodeficiency virus (HIV) type 1 |
| Assessment Process | |
| Rapid review commissioned | 26/04/2016 |
| Rapid review completed | 26/04/2016 |
| Rapid review outcome | Full Pharmacoeconomic Evaluation Recommended at the Submitted Price. |
The HSE has approved reimbursement following confidential price negotiations.
